-
Ardea Biosciences Reports Q4 EPS of $(0.03) vs. $(0.59)
Friday, March 11, 2011 - 9:36am | 85Ardea Biosciences, Inc. (Nasdaq: RDEA) today reported recent accomplishments and announced fourth quarter 2010 financial results. Revenues totaled $17.3 million and $27.4 million for the three and twelve months ended December 31, 2010, respectively. Net loss for the three and twelve months...
-
ISS Proxy Advisory Services Recommends That CPEX Stockholders Vote for Merger Agreement
Friday, March 11, 2011 - 9:31am | 111CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that ISS Proxy Advisory Services has recommended that CPEX stockholders vote "FOR" CPEX's proposed merger agreement with FCB I Holdings Inc., under which CPEX stockholders will receive $27.25 per share in cash. The transaction price...
-
Piper Jaffray Reiterates Overweight on Medicis Pharmaceutical (MRX)
Friday, March 11, 2011 - 8:57am | 133Piper Jaffray is out with its report today on Medicis Pharmaceutical (NYSE: MRX), reiterating Overweight. In a note to clients, Piper Jaffray writes, "We spent yesterday with Medicis management meeting with investors. We came away confident that the company will be able to settle lingering generic...
-
Piper Jaffray Maintains Neutral Rating On JNJ
Friday, March 11, 2011 - 8:43am | 171Johnson & Johnson's (NYSE: JNJ) announcement that it entered into a consent with the FDA effectively transforms the McNeil issues from a horizon of potentially 1-2 years to something closer to 4-5 years, Piper Jaffray reports. “In addition to lost product revenues, which totaled $900 mil for...
-
Benzinga's Top Upgrades (AFFY, SPPI, ARAY, NSC)
Friday, March 11, 2011 - 8:37am | 143Affymax Inc (NASDAQ: AFFY) was upgraded by Auriga from "hold" to "buy." AFFY's shares closed at $6.61 yesterday. Affymax's trailing-twelve-month revenue is $138.75 million. Capstone upgraded Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) from “hold” to “buy.” SPPI's shares closed at $7.58 yesterday....
-
Benchmark Reports Columbia Labs' Q4 Pro-Forma Beats Forecasts
Friday, March 11, 2011 - 8:25am | 145In a report published by Benchmark, Columbia Laboratories' (NASDAQ: CBRX) Q4 pro-forma beats forecasts but the focus remains on study data publication and NDA Filing. Benchmark said that Columbia reported Q4 results that were slightly better than anticipated but its focus remains Management's...
-
Wells Fargo Ups SLXP To Outperform
Friday, March 11, 2011 - 6:56am | 46Analysts at Wells Fargo upgrade Salix Pharmaceuticals Ltd (NASDAQ: SLXP) from “market perform” to “outperform.” SLXP shares closed at $32.54 yesterday. More Analyst Ratings here
-
Fast Money Pops & Drops, March 10th (IRM, HGSI, NTAP, SFD)
Thursday, March 10, 2011 - 9:10pm | 246Karen Finerman said on CNBC's Fast Money Pops & Drops that Elliott management announced that it wants to put its nominees on the board of directors of Iron Mountain Incorporated (NYSE: IRM). Karen Finerman thinks that this stock is worth of taking a look. Iron Mountain Incorporated (IRM) gained...
-
Mad Money Lightning Round OT: Cramer Gives His Opinion On OPTR, ALK And CCME
Thursday, March 10, 2011 - 8:36pm | 224On CNBC's Mad Money Lightning Round OT, Jim Cramer said that Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) is a speculative play. It is a part of pharmaceutical diversified portfolio, and Cramer believes that it is too risky. He is not a buyer of this stock. Optimer Pharmaceuticals, Inc. (OPTR) fell...
-
Biodel Director Steinger Sells 170K Shares (BIOD)
Thursday, March 10, 2011 - 5:13pm | 22In A Public Filing, Biodel Director Steinger Sells 170K Shares (NASDAQ: BIOD).
-
Optimer Pharma Beats EPS Estimates: ($0.31) Vs. ($0.33) Est. (OPTR)
Thursday, March 10, 2011 - 5:09pm | 19Optimer Pharma Beats EPS Estimates: ($0.31) Vs. ($0.33) Est. (NASDAQ: OPTR)
-
Standard & Poor's Upgrades Mylan
Thursday, March 10, 2011 - 3:19pm | 94Mylan Inc. (Nasdaq: MYL) today reported that Standard & Poor's Ratings Services upgraded the company's corporate credit ratings to 'BB+' from 'BB.' S&P also upgraded Mylan's senior secured rating to 'BBB' from 'BBB-' and raised the company's senior unsecured rating to 'BB' from 'BB-'....
-
Health Insurers Triple S&P 500 Returns
Thursday, March 10, 2011 - 1:21pm | 664By Josh Lipton In the past month, while violent unrest in the Middle East and North Africa has dramatically dominated the investment headlines, strategists note that one sector has quietly emerged under the radar: Health Care. In fact, month-to-date, the S&P 500 is down .41%. However, there...
-
Benzinga's Volume Movers (HGSI, GMCR, SMTC, SBUX)
Thursday, March 10, 2011 - 11:47am | 214Human Genome Sciences Inc (NASDAQ: HGSI) shares moved up 9.64% to $28.16 at 10:45 am. The volume of HGSI shares traded was 2533% higher than normal. GlaxoSmithKline Plc (NYSE: GSK) and HGSI received the Food and Drug Administration (FDA) approval for Benlysta, the first new drug to treat lupus in...
-
Stocks on the Move:(SPPI) Break Out Year High
Thursday, March 10, 2011 - 10:50am | 18Stocks on the Move:(SPPI) Break Out Year High..